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Summary
Background There is no consensus on core outcome domains for hidradenitis sup-
purativa (HS). Heterogeneous outcome measure instruments in clinical trials likely
leads to outcome-reporting bias and limits the ability to synthesize evidence.
Objectives To achieve global multistakeholder consensus on a core outcome set
(COS) of domains regarding what to measure in clinical trials for HS.
Methods Six stakeholder groups participated in a Delphi process that included five anony-
mous e-Delphi rounds and four face-to-face consensus meetings to reach consensus on
the final COS. The aimwas for a 1 : 1 ratio of patients to healthcare professionals (HCPs).
Results A total of 41 patients and 52 HCPs from 19 countries in four continents
participated in the consensus process, which yielded a final COS that included
five domains: pain, physical signs, HS-specific quality of life, global assessment
and progression of course. A sixth domain, symptoms, was highly supported by
patients and not by HCPs but is recommended for the core domain set.
Conclusions Routine adoption of the COS in future HS trials should ensure that
core outcomes of importance to both patients and HCPs are collected.
What’s already known about this topic?
• Outcome measure instruments used for hidradenitis suppurativa (HS) are markedly
heterogeneous with 30 instruments recently found in 12 randomized trials.
• Lack of consensus regarding outcome measure instruments limits evidence synthe-
sis and increases the risk of outcome reporting bias.
• A core domain set is an agreed minimum set of what to measure that should be
reported in all clinical trials of a specific condition.
What does this study add?
• Our study provides global multistakeholder consensus on core outcome domains for HS.
© 2018 The Authors. British Journal of Dermatology
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• The final core domain set includes five domains: pain, physical signs, HS-specific
quality of life, global assessment and progression of course.
• A sixth domain, symptoms, was highly supported by patients and not by healthcare
professionals; it is recommended by the steering committee as an additional core
domain, in the context of being a patient-reported domain.
What are the clinical implications of this work?
• The routine adoption of this core outcome set in future HS trials should ensure
that outcome domains of importance to both patients and HCPs are included and
reported.
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin
disease with an estimated prevalence of 01–4% worldwide.1–4
The primary lesions are inflammatory nodules that may
develop into abscesses and sinus tracts with subsequent scar-
ring, affecting flexural sites such as the axillae and groins on a
recurrent basis.5,6 Lesions of HS are typically described by
patients as painful boils which, along with associated pus and
odour, may have a large impact on quality of life.7–11
Interventions for HS are diverse and include topical treat-
ment, systemic antibiotics, retinoids, immunomodulatory oral
therapy, biological drugs, laser therapy and surgery.12,13 The
level of evidence for existing treatments is low, suggesting a
particular need for more clinical trials in HS.13
Validated outcome measure instruments are necessary to
ensure that study results are comparable and that, as a conse-
quence, patients receive the most effective interventions. For
HS, numerous outcome measure instruments exist, with a
total of 30 instruments used in the 12 randomized controlled
trials included in the recent Cochrane review.13,14 Heterogene-
ity of outcome measure instruments in HS limits evidence
synthesis, including meta-analysis13 and likely leads to out-
come reporting bias because of selective reporting of more
favourable outcomes.15 Because no consensus on core out-
comes for HS exists, researchers use various instruments,
which may or may not be valid. Furthermore, current instru-
ments emphasize clinical features with limited incorporation
of patient-reported outcomes, despite recommendations
emphasizing the importance of the patient perspective in out-
comes research.16
To tackle these issues, the HIdradenitis SuppuraTiva cORe
outcomes set International Collaboration (HISTORIC) was
formed as a collaboration between the International Dermatol-
ogy Outcome Measures (IDEOM) initiative, the Cochrane Skin
Group – Core Outcome Set Initiative and Zealand University
Hospital, Roskilde. The first HISTORIC goal was to develop a
core outcome set (COS) of domains that is relevant to all
major stakeholders, including patients, to be recommended
for use in all subsequent HS clinical trials.17–19 We performed
and moderated an international multiperspective Delphi con-
sensus project with the scope to develop a COS suitable for all
HS clinical trials. The COS is intended to suit all types of
interventions for all HS patients, regardless of setting or mode
of administration.
Materials and methods
The study is reported in accordance with the newly developed
Core Outcome Set STAndards for Reporting (COS-STAR).20 A
detailed description of the methods can be found in our proto-
col article.21 Methodological guidance was followed from Core
Outcome Measures in Effectiveness Trials (COMET)19 and Out-
come Measures in Rheumatology (OMERACT).22 We were also
guided by the Harmonizing Outcome Measures for Eczema
(HOME) roadmap.23 The methodology involves a stepwise
approach for the development of a COS. The first step is to iden-
tify which domains one should measure and report in all clinical
controlled trials of a specific condition (what to measure: the
core domain set).15 The second step is to identify the instru-
ments that should be used to assess these domains (how to mea-
sure: the core outcome measurement set).17,19 The present
study achieved the first step, determining what to measure.
Participants
The involvement of multiple stakeholders for the development
of a COS is strongly recommended by methodolo-
gists.17,19,23,24 Six groups of stakeholders were invited to par-
ticipate in our development process: patients, dermatology HS
experts, surgical HS experts, HS nurses, industry representa-
tives and drug regulatory authorities. Patients were analysed as
one stakeholder group and the remaining stakeholder groups
were combined into a second group referred to as healthcare
professionals (HCPs). The HCP group contained one represen-
tative of a drug regulatory authority (the European Medicines
Agency) and one industry representative. Other drug regula-
tors and pharmaceutical companies with an interest in HS
were contacted but chose not to contribute. The aim was for a
1 : 1 ratio of patients to HCPs.
Patients were identified through patient associations and via
dermatologists with a special interest in HS in countries with-
out a formal patient association. HCPs were identified from the
community of HCPs working with patients with HS. A clinical
© 2018 The Authors. British Journal of Dermatology
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background of at least 5 years of experience managing HS was
required for all HCPs and publications on HS or participation
in scientific meetings on HS was required for dermatologists.
Information sources
The initial list of candidate items was obtained in a three-step
manner.
1 Systematic review of literature. A recent systematic Cochrane
review on interventions for HS and another systematic
review on outcome measure instruments reviewed the
validation evidence for existing instruments and mapped
them according to potential domains.13,14
2 Qualitative studies. Semistructured interviews and focus groups
were conducted at the Department of Dermatology, Zealand
University Hospital, Roskilde, Denmark and the Department
of Dermatology, Penn State College of Medicine, Hershey,
Pennsylvania, U.S.A. Purposive sampling of a wide diversity
of age groups, sex, treatments received and disease severities
was employed. Inclusion of patients ceased when saturation
was achieved, defined as when no new knowledge was
obtained from the subsequent interviews. Patients were iden-
tified primarily among those undergoing treatment at the
two Departments of Dermatology. Eligibility was based on a
confirmed diagnosis of HS and willingness to participate.
All interviews were tape recorded and transcribed verbatim
and initially examined for units of meaning, coded as
items and grouped into categories. Qualitative interviews
do not require ethical approval in Denmark. In the U.S.A.
the project was approved by the institutional review board
of the Penn State College of Medicine. The two lists of
candidate items generated from the Danish and US qualita-
tive studies were combined into one patient-generated item
list.
3 Identification of items of importance to healthcare professionals. To
identify outcomes of importance to HCPs an item genera-
tion e-Delphi round zero was conducted among the HCP
stakeholders. Participants were first provided with back-
ground information on the rationale for development of
an HS COS. They were then asked to list all items that
they considered important regarding HS, with items being
related to any aspect of the disease, or treatment of the
disease.
The steering group reviewed all items suggested by the HCPs
and produced a preliminary list of candidate items by combin-
ing the results from the systematic reviews, the qualitative
studies and the HCPs item generation survey.
Consensus process
A summary of the consensus process is shown in Figure 1. An
international steering group (the first 12 authors of this manu-
script) consisting of researchers, clinicians and a patient
research partner guided development of the COS.
Systematic 
review of 
literature
Qualitative  
studies
Identification of initial 
list of candidate items 
and potential core 
domains
HCP item 
generation
survey 
Combined 
list of 
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items 
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Fig 1. Study summary. HCP, healthcare professional.
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Methods to reach consensus on the core domain set
An anonymous Delphi approach was applied to make sure
that the views of all participants were obtained. The e-Delphi
survey was delivered using DelphiManager (round one and
two, COMET Initiative, http://www.comet-initiative.org/de
lphimanager/) and SurveyMonkey (round three to five,
SurveyMonkey, San Mateo, CA, U.S.A.) software. A unique
identifier code allowed identification of participants complet-
ing all rounds of the Delphi survey. Only participants who
had completed the previous round of the survey were
invited to participate in subsequent rounds. All surveys were
pilot-tested by at least two members of the steering group,
including the patient representative, and at least two addi-
tional panel members.
Items/domain scoring
Participants were asked to score each item/domain using a
modified scale from the Grading of Recommendations, Assess-
ment, Development and Evaluations (GRADE) from one to
nine. Explanation was provided that scores of one to three are
‘not important’, scores of four to six are ‘important but not
critical’ and scores of seven to nine are ‘critical’ to include.25
From round two of the Delphi onwards, participants were
provided with feedback in the form of their own scores in the
previous round and the aggregate scores from the previous
round, subdivided into the patient and HCP groups.
Definition of consensus
Prespecified consensus end points are outlined in Table 1.
E-Delphi round one and two
Participants were provided with background information
explaining how the candidate items were identified and were
then asked to rate each of the items listed, based on their
importance in being measured as an outcome in all clinical
trials for HS. Participants were also asked to suggest items not
represented in the list. Items suggested were reviewed by the
steering group to ensure they represented new items and all
items were carried forward to round two. In round two, the
number of participants who ranked each item and the distri-
bution of scores (as percentages of the total) by stakeholder
group from round one were shown graphically in the survey
and participants were asked to consider responses from other
panel members and to re-score all items. All items were car-
ried forward to consensus meeting I and II and e-Delphi
round three.
HIdradenitis SuppuraTiva cORe outcomes set International
Collaboration consensus meeting I and II
After the first two e-Delphi rounds, participants were invited
to take part in two in-person consensus meetings (Vienna,
September 2016 and New York, October 2016). In these
meetings, patients and HCPs collaborated on nominating items
for exclusion based on round two e-Delphi results and group-
ing remaining candidate items into domains. The process of
defining domains was achieved in small groups using nominal
group theory. Prior to the nominal group exercise, participants
were made aware that items could form their own stand-alone
domain or be collected into an umbrella domain, if the items
were sufficiently congruent and capable of being measured by
a single instrument.
As only a subset of the e-Delphi group was able to attend
the in-person meetings, all decisions taken at the meetings
required confirmation by the larger HISTORIC project group
Table 1 Definition of consensus
Consensus
classification Description Definition
Consensus in Consensus that the item/domain should be included in the core
domain set
70% or more participants scoring 7 to 9 AND < 15%
participants scoring 1 to 3
Consensus out Consensus that the item/domain should not be included in the
core domain set
70% or more participants scoring 1 to 3 AND < 15%
of participants scoring 7 to 9
No consensus Uncertainty about importance of the item/domain Anything else
Table 2 Characteristics of patients with hidradenitis suppurativa, item
generation interviews
Variables
North American
patients (n = 21)
Danish patients
(n = 21)
Age, years 468  137 379  108
Women, n (%) 16 (76) 13 (62)
Ethnicity, n (%)
Non-Hispanic white 13 (62) 21 (100)
Hispanic 3 (14) 0
Black 2 (10) 0
Asian 1 (5) 0
Mixed ethnicity 2 (10) 0
Hurley stage, n (%)
1 0 3 (14)
2 12 (57) 12 (57)
3 9 (43) 6 (29)
Disease durationa, years 205  127 198  100
Data is presented as mean  SD unless otherwise stated. aMissing
values for three of the Danish patients.
© 2018 The Authors. British Journal of Dermatology
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Table 3 List of all items initially included in the Delphi exercise (item 57 included after the first round)a
Item
number Item name Help text
Item
number Item name Help text
1b Biomarkers Measures of disease presence or activity
in blood samples
30b Dyspigmentationb Changes (lighter or darker) to the
normal colour of your skin
2 Drainage Secretion, blood, stains, suppuration 31 Anatomical location Body areas and number of body areas
involved
3 Oedema Swelling of the skin 32c Number of
inflamed nodules
Number of red, painful or tender
nodules
4 Economic
burden
Economic burden to the patient related
to the disease (e.g. doctor appointments,
surgery, medication), management
(e.g. bandages, pads, or diet), time lost
33 Psychological
functioning
Feelings of depression, apathy,
loneliness, suicidal thoughts.
Feelings of irritation, anxiety, stress
5 Coping Being able to handle (cope with) having
the disease
34c Health-related
quality of life
Perceived physical, mental and social
health over time
6 Odour Unpleasant odour 35c Number of
fistulae
Number of connections to skin surface
7c Satisfaction
with
treatment
Satisfaction with effectiveness; time spent
on treatment
36c Pain Pain
8 Adverse
effects of
surgical
treatments
All types of side-effects from surgical
treatments (e.g. bleeding, infection,
contractures)
37 Cognition Impact on concentration (e.g. at work
or at school, or in leisure activities)
9c Number of
cysts
Number of sac-like pockets under the
skin which contain fluid or debris from
the skin
38 Fatigue Physical weariness sometimes
combined with mental weariness
10 Comorbidities Associated diseases, e.g. metabolic
syndrome, PCOS or other inflammatory
diseases
39 Cosmesis Visual appearance of a person’s skin
from his/her own perspective
related to the disease and surgery for
the disease
11 Intimacy Impact on sexual health, having desire or
feeling desired, pain during sexual
activity, abstaining from sex, fear of
being rejected
40c Patient global
evaluation
Overall assessment of the disease
from the perspective of the patient
himself or herself, alone and without
the influence of anyone else
12 Ability to
work or
study
Ability to work or study, ability to gain
or keep employment, influence on type
of job or study, time off from work or
study, impact on career
41 Washing or
bathing
Ability to wash or bathe oneself;
having to frequently wash or bathe
oneself
13 Adverse
effects of
medical
treatments
All types of side-effects from medical
treatments
42b Ulceration Absence of upper layers of the skin
forming an ulcer
14c Number of
noninflamed
nodules
Number of skin coloured nodules which
may not be painful or tender
43c Physician global
evaluation
Overall assessment of the disease from
the perspective of the physician alone
15 Itch Itch 44c Number of sinus
tracts
Number of tunnel-like connections
between lesions
16 Self-treatment,
not
prescribed
Self-treatment which is not prescribed
(e.g. self-incision to obtain pain relief,
placing ice cubes or warm compresses
on boils)
45 Scarring from
surgery
Scars resulting from surgery
17c Number of
abscesses
Number of collections of pus (sterile or
infected)
46b Complianceb A patient’s adherence to a
recommended course of treatment
18c Total lesion
count
Total number of all types of lesions 47 Satisfaction with
care
Access to care, satisfaction with the
doctor’s knowledge of disease,
quality of care, feeling supported
by medical personnel
(continued)
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in a subsequent online confirmation survey before implemen-
tation. Prior to completion of the survey, e-Delphi panel
members were provided with a summary of the in-person
meeting discussions. A detailed description of consensus meet-
ing I and II and the online confirmation survey has been
published.26
E-Delphi round three
In round three, the items were shown under their newly des-
ignated domain, following the work from the in-person meet-
ings. Items that were marked for exclusion at the consensus
meetings were shown at the end, under a heading of ‘marked
for exclusion’. Items that were marked for exclusion and did
not reach ‘consensus in’ were not carried forward to round
four.
HIdradenitis SuppuraTiva cORe outcomes set International
Collaboration consensus meeting III
After the third e-Delphi round, it was noted that some items
and domains were considered ‘critical’ to include in the COS
only by patients or HCPs but not both. These discordant items
were discussed by patients and HCPs at a third in-person con-
sensus meeting (Copenhagen, February 2017). This discussion
was followed by nonbinding voting.
E-Delphi round four and five
In round four, participants voted at the domain level for the
first time and voted again on items within each domain that
had still not reached clear ‘consensus in’. A summary of the
discussion and voting results from consensus meeting III were
Table 3 (continued)
Item
number Item name Help text
Item
number Item name Help text
19 Psychosocial
functioning
Feelings of being accepted by others,
nervous to be in public, withdrawn
from relationships
48 Independence Need to be independent, not to be
dependent on others
20 Scarring from
HS
Scar formation in involved areas 49c Time to postop
recovery
Time to healing after surgery
21 Need for
treatment
and bandages
Requirements for prescribed treatment,
for example acute treatment, pain killers,
topic treatment, in-hospital treatment
and bandages
50 Clothing
restrictions
Impact on choice of clothing (e.g.
choosing clothes that do not irritate
lesions, that cover lesions, that cover
stains)
22 Surface area Area of the skin surface involved 51 Flare frequency Frequency of flares
23 Impact on
close
relationships
Impact on relationship to partner or
family member, neglect of family, poor
understanding of disease by family
52c Inflammatory
lesion count
Total number of all red, painful or
tender lesions (abscesses or inflamed
nodules)
24c Time to
recurrence
Time to reappearance of activity, such as
after surgery or after ending medical
therapy
53b Comedones Appearance of small ‘blackheads’ on
the surface of the skin formed by the
blockage of pores
25 Emotional
well-being
Feelings of powerlessness, embarrassment,
low self-esteem
54 Constitutional
symptoms
The experience of one or more
symptom(s) associated with the
development of new lesions (e.g.
fatigue, fever-like sensation, headache)
26c Decreased
mobility
Decreased mobility, skin tightness, may
be associated with restrictions in
exercising, walking, reaching out,
standing, sitting, activities of daily living
(e.g. housework)
55b Erythema Redness of the skin
27 Satisfaction
with social
roles
Satisfaction with oneself as a partner,
parent, family member, friend or
colleague
56 Sleep disturbance Difficulty sleeping, inability to sleep,
poor quality of sleep
28b Progression
of course
Worsening of disease, prevention of
worsening
57 Number of
chronic areas
Number of chronic areas open for
more than 6 weeks
29 Recreation
and leisure
activity
Interference with leisure/recreational
activities (e.g. sports, do-it-yourself,
playing instruments, scouting, hiking
or outdoor life). Interference with
planning of such activities
aThe help text was shown with each item in the e-Delphi. The item numbers were generated at random before round one of the e-Delphi;
bitems generated in the healthcare professionals item generation survey; citems generated in the review of the literature and re-found in
patient interview qualitative studies. Remaining items were generated in the patient interview qualitative studies.
© 2018 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2018) 179, pp642–650
Core domain set for hidradenitis suppurativa trial outcomes, L. Thorlacius et al. 647
provided, in addition to the results from e-Delphi round three.
In round five, participants voted on two domains for which
consensus was nearly achieved (more than 67% combined
critical votes) to determine whether these should be included
in the COS.
HIdradenitis SuppuraTiva cORe outcomes set International
Collaboration consensus meeting IV
The results of e-Delphi rounds one to five and HISTORIC in-
person consensus meetings I–III were presented at the annual
IDEOM meeting in Washington, DC in May 2017. All meeting
participants were asked if they considered the HISTORIC HS
COS process to be methodologically robust and inclusive and
if the project had developed an appropriate COS. Consensus
for the final core domain set was defined as > 70% of all par-
ticipants voting yes to both these questions.
Results
Participants
Patient characteristics from the qualitative studies are found in
Table 2 and demographics of all Delphi participants are found
in Table S1 (see Supporting Information). A total of 42
patients participated in the qualitative studies and a total of 93
(41 patients and 52 HCPs) from 19 countries in four conti-
nents participated in the first round of the e-Delphi. In the last
round of the e-Delphi, 78 participants continued to take part,
a 16% attrition rate. Of the 15 individuals who dropped out,
nine were patients and six were HCPs, with nine from North
America and six from other continents.
Candidate outcome items and domains
A list of all 56 items initially included in the Delphi exercise
is found in Table 3. The systematic review identified 16
potential candidate items, 33 additional items were identified
by patients in the qualitative studies and the HCP item gener-
ation survey identified seven further items (Table 3). One
item suggested by a patient participant in the first e-Delphi
round (number of chronic areas) was judged to represent a
new outcome and added to the list of candidate items in
round two and subsequent rounds. Item numbers 1, 4, 7, 8,
10, 13, 16, 30, 39, 41, 45, 47, 53 (Table 3) were nomi-
nated for exclusion following consensus meetings I and II,26
did not reach ‘consensus in’ in e-Delphi round three and
were therefore excluded. One item, ‘Pain’ was ranked so
highly by both patients and HCPs that it was nominated to
form a domain in its own right. Other domains were formed
Sleep disturbance
Pain
Physical signs
Anatomical locaon, Surface area, Total lesion count, 
Inﬂammatory lesion count, Number of abscesses, 
Number of inﬂamed nodules, Number of sinus tracts, 
Number of ﬁstulae 
HS speciﬁc quality of life
Physical funconing, Psychological funconing, 
Psychosocial funconing, Emoonal well-being, Ability 
to work or study
Global assessment
Paent global , Physician global  
Progression of course
Flare frequency and duraon, Time to recurrence
Number of 
chronic 
areas 
Symptoms
Drainage, Fague Biomarkers
Time to heal
(a) (b) (c)
Fig 2. The final core domain set in an adapted Outcome Measures in Rheumatology (OMERACT) onion model. (a) Inner ring: the core set,
domains (in black) and items (in white) that reached ‘consensus in’ for patients and healthcare professionals (HCPs). (b) Middle ring: domains
(in black) and items (in white) that reached ‘consensus in’ for patients or HCPs. (c) Outer ring: items that did not reach ‘consensus in’, but were
marked at consensus meetings for the research agenda or important in specific trials. HS, hidradenitis suppurativa.
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by collecting together similar items during the nominal group
exercises, as detailed in the report of consensus meetings I
and II.26
The final core domain set
The final core domain set is illustrated in Figure 2. After the
last e-Delphi and the final consensus meeting, the participants
agreed to include five domains in the HS COS for clinical tri-
als: pain, physical signs, HS-specific quality of life, global
assessment and progression of course. The domains are further
defined by the items that were fused in the process of creating
domains (Fig. 2). A ‘symptoms’ domain, containing the items
‘drainage’ and ‘fatigue’, was strongly supported by patients
but did not quite reach our a priori definition of ‘consensus
in’ from the perspective of HCPs.
In total, 79% of consensus meeting IV participants consid-
ered the HISTORIC COS process to be inclusive and method-
ologically robust and 82% felt that an appropriate COS had
been achieved and voted to ratify the HISTORIC COS.
Protocol deviations
The HISTORIC consensus meeting III was not planned a priori
but was added after round three to allow further discussion of
some items and domains where disagreement between
patients and HCPs was identified. E-Delphi round five was
added after round four to discuss domains where consensus
had nearly, but not quite, been achieved. This resulted in
inclusion of the ‘progression of course’ domain in the final
COS, but did not affect lack of consensus between HCPs and
patients regarding the symptoms domain. As no items or
domains ever reached the predefined ‘consensus out’ rule in
any rounds, the process focused only on the predefined ‘con-
sensus in’ rule. By comparing the proportions voting critical
among HCPs and patients, when both proportions were above
70% threshold, these items/domains were considered part of
the COS.
Discussion
We used a rigorous, iterative and inclusive approach to iden-
tify consensus among an international group of patients with
HS and HCPs, producing five core domains relevant for all
types of clinical trials for HS, namely pain, physical signs, HS-
specific quality of life, global assessment and progression of
course. There was close agreement among all stakeholders to
include the final five domains in the COS. Based on our proto-
col, the symptoms domain is not included as a core domain
because it only reached ‘consensus in’ from the patient per-
spective and support was insufficient from HCPs. However,
the HISTORIC steering group reflected that, because symptoms
is a patient-reported domain and was considered critical by
our patient participants, the patient view supersedes that of
HCPs in this instance. As a result, the HISTORIC steering
group agreed that the symptoms domain should be included
in step two of the COS process to search for a suitable instru-
ment for the domain.
Limitations to the present study include that our aim to
involve a 1 : 1 ratio of patients to HCPs was not completely
reached and that we did not succeed in involving participants
from the continents of Africa and South America in the project.
The HISTORIC initiative has begun the process to develop a
COS for HS trials. The implementation of a COS for HS clinical
trials should improve the interpretation and comparison of
future studies testing interventions for HS and reduce the risk
of outcome reporting bias and heterogeneity across studies.
After achieving consensus on what to measure in HS clinical
trials, the next step for the HISTORIC initiative will be to reach
consensus on the outcome measurement instruments best sui-
ted to measure each of the core domains in the COS.
In conclusion, our present study reports on the robust
development of a comprehensive COS for use in all trials
assessing interventions for HS. The final COS includes five core
outcome domains agreed by both patients and HCPs and a
sixth domain, symptoms, is recommended by the HISTORIC
steering group because it is a patient-reported domain that
received strong support from our patient stakeholder group.
The routine adoption of this COS in future HS trials should
ensure that outcome domains of importance to both patients
and HCPs are included and reported.
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